We read with interest the recent report by Schuval et al1 regarding the Pediatric AIDS Clinical Trials Group Protocol (PACTG) 1028S study on coinfection with hepatitis C virus (HCV) in children infected with human immunodeficiency virus 1 (HIV-1). The goal of the study was commendable, though the small number of coinfected children who were identified highlights the difficulties inherent to the study of this population. Given these limitations, enrollment might have been increased by including children younger than 1 year. Concerns over false-positive results due to maternal antibodies are unwarranted when HCV RNA testing is performed. In retrospect, it is unfortunate that only a subset of the 3000 subjects in the PACTG 219C study were enrolled in this substudy.
Martin SR, Lapointe N, Soudeyns H. Coinfection With Hepatitis C Virus and Human Immunodeficiency Virus 1 in Children: Pathogenesis and Screening. Arch Pediatr Adolesc Med. 2005;159(6):596–599. doi:10.1001/archpedi.159.6.598